✦ LIBER ✦

Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?

✍ Scribed by Leticia De Mattos-Arruda; Javier Cortes

Book ID: 113507623
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 376 KB
Volume: 21
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2012.04.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HER-2/neu Overexpression and Tumor Subty

HER-2/neu Overexpression and Tumor Subtyping: Is there an Increased Risk of Axillary Node Positivity in Early Stage Breast Cancer?

✍ M.A. Hallman; G.M. Freedman; R.J. Bleicher; T. Li; P.R. Anderson; E.R. Sigurdson 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Prognosis of metastatic breast cancer su

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

✍ Lobbezoo, Dorien J. A.; Kampen, Roel J. W.; Voogd, Adri C.; Dercksen, M. Wouter; 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 309 KB

415 Investigating the Role of HER4 in Re

415 Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer

✍ Nafi, S. Mohd; Kong, A.; Gijsen, M.; Kramer-Marek, G.; Capala, J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Benefit of continuing trastuzumab beyond

Benefit of continuing trastuzumab beyond progression in her2-positive metastatic breast cancer (mbc) is independent of the chemotherapy partner: message from a single-centre retrospective study

✍ Raffaella Palumbo; Federico Sottotetti; Antonio Bernardo; Maria Rosa Strada; Alb 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB

The immunohistochemically “ER-negative,

The immunohistochemically “ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative” subgroup is not a surrogate for the normal-like subtype in breast cancer

✍ Ke-Da Yu; Zhen-Zhou Shen; Zhi-Ming Shao 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 307 KB

Is there a role for microsurgery in the

Is there a role for microsurgery in the prevention of arm lymphedema secondary to breast cancer treatment?

✍ C. Campisi; D. Davini; C. Bellini; G. Taddei; G. Villa; E. Fulcheri; A. Zilli; E 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract The secondary lymphedema of the upper limb (post‐mastectomy lymphedema) has an incidence, in patients who underwent axillary lymphadenectomy for breast cancer, between 5 to 25%, up to 40% after radiotherapic treatment. We studied 50 patients treated for breast cancer. The patients were